New hope for HER2 cancers: first human trial launches
NCT ID NCT05523947
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental drug called YH32367 in people with HER2-positive solid tumors that have spread or cannot be removed by surgery. The study has two parts: first, finding a safe dose, then testing that dose in specific cancer types like biliary tract cancer. About 147 participants will be enrolled to check safety, how the drug moves through the body, and whether it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YH32367 (an experimental drug)
What this could lead to
If successful, this could point toward a new treatment option for people with HER2-positive cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early first-in-human study, so safety and effectiveness are not yet known. The drug may not shrink tumors or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ajou University Hospital
RECRUITINGSuwon, Gyeonggi-do, 16499, South Korea
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Austin Health
RECRUITINGMelbourne, Australia
-
Blacktown Hospital
RECRUITINGSydney, Australia
-
Breast Cancer Research Centre - WA
WITHDRAWNPerth, Australia
-
CHA Bundang Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
-
Catholic University of Korea St. Vincent's Hospital
RECRUITINGSuwon, Gyeonggi-do, 16247, South Korea
-
Chungbuk National University Hospital
RECRUITINGCheongju-si, North Chungcheong, 28644, South Korea
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Gachon Gil University Medical Center
RECRUITINGIncheon, 21565, South Korea
-
Gyeongsang National University Hospital
RECRUITINGJinju, Gyeongsangnam-do, 52727, South Korea
-
Korea University Anam Hospital
RECRUITINGSeoul, 02841, South Korea
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
Southern Oncology Clinical Research Unit
TERMINATEDAdelaide, Australia
-
The Catholic University of Korea, St. Mary's hospital
RECRUITINGSeoul, 06591, South Korea
-
Ulsan University Hospital
RECRUITINGUlsan, 44437, South Korea
-
Vanderbilt Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States